ENA101 / Enara Bio - LARVOL DELTA

ENA101: A first-in-class bispecific T cell engager targeting a DARKFOX peptide presented by solid tumors (AACR 2026) - "This mechanism enables potent immune activation and has delivered landmark clinical benefit in solid tumors, exemplified by tarlatamab and tebentafusp, which achieved unprecedented efficacy even in immunologically 'cold' settings such as small-cell lung cancer and uveal melanoma. ENA101 exhibits the hallmarks of a best-in-class bispecific T cell engager for solid tumors, including potent and highly specific redirection of T cell activity against antigen-positive cells across multiple tumor types. CMC activities and IND-enabling studies are currently in progress."

Bispecific • First-in-human • IO biomarker • Eye Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Uveal Melanoma • FOXM1

Discovery and validation of DARKFOXTM, a novel alternative open reading frame of FOXM1 that is an attractive cancer antigen for peptide-HLA targeting immunotherapy (SITC 2025) - "Background Targeted immunotherapies are a highly promising treatment strategy for solid tumors, exemplified by the recent FDA approvals of tebentafusp and afamitresgene autoleucel, which target Class I peptide-HLA (pHLA) antigens...It is characterised by minimal presence in normal tissues, homogeneous intratumoral expression, and robust presentation by HLA on the surface of tumor cells. ENA101, an EnTiCE® bispecific T-cell engager targeting DARKFOX-A3, is currently in IND-enabling studies."

IO biomarker • Esophageal Adenocarcinoma • Esophageal Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOXM1

Discovery and validation of DARKFOXTM, a novel alternative open reading frame of FOXM1 that is an attractive cancer antigen for peptide-HLA targeting immunotherapy (SITC 2025) - "Background Targeted immunotherapies are a highly promising treatment strategy for solid tumors, exemplified by the recent FDA approvals of tebentafusp and afamitresgene autoleucel, which target Class I peptide-HLA (pHLA) antigens...It is characterised by minimal presence in normal tissues, homogeneous intratumoral expression, and robust presentation by HLA on the surface of tumor cells. ENA101, an EnTiCE® bispecific T-cell engager targeting DARKFOX-A3, is currently in IND-enabling studies."

IO biomarker • Esophageal Adenocarcinoma • Esophageal Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOXM1

Enara Bio’s DARKFOX Discovery Propels ENA101, the First Ever Bispecific T Cell Engager Targeting a Cancer-Specific Dark Antigen, into IND-Enabling Studies (GlobeNewswire) - "Enara’s discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically actionable Dark Antigens and will be highlighted in an oral presentation at SITC 2025. DARKFOX demonstrates best-in-class target properties: high tumor specificity, homogeneous expression in tumors and high prevalence in significant patient populations including lung, breast and GI cancers....ENA101 is advancing into IND-enabling studies with clear development path to submission in 2026."

IND • Preclinical • Breast Cancer • Gastrointestinal Cancer • Non Small Cell Lung Cancer